brain stimulation
The M&A is expected to help Flow expand to treat new mental health conditions that are commonly comorbid with depression.
The system may now be used to target patients' internal globus pallidus, a portion of the brain associated with Parkinson's disease symptoms.
Sweden-based Flow landed $1.5 million in funding from Khosla Ventures.